Literature DB >> 203636

Central nervous system immunity in mice infected with theiler's virus. I. Local neutralizing antibody response.

H L Lipton, F Gonzalez-Scarano.   

Abstract

Experimental Theiler's mouse encephalomyelitis virus (TMEV) infection in mice is atypical of most other picornavirus infections because virus persists in the host. It was shown previously that low levels of infectious virus are readily detectable in the central nervous system (CNS) despite the presence of substantial titers of serum neutralizing antibody. In this study antibody assays were performed on CNS tissue homogenates, and neutralizing antibody was regularly found in the CNS of TMEV-infected mice. That neutralization by infected CNS extracts was due to antibody was demonstrated by the specificity of neutralization for TMEV and by elimination or marked reduction of neutralization by in vitro treatment with goat antiserum to mouse IgG. In addition, immunofluorescent staining consistently revealed IgG- but not IgM-containing cells in perivascular cuffs and parenchymal lesions of the brains of infected animals. Evidence of local antibody formation in the CNS was found in the actual reversal of the serum-CNS antibody ratio in about one-third of infected mice after three weeks. In contrast, normal mice had a mean serum-CNS antibody ratio of approximately 100:1 after passive transfer of antibody. Possible reasons for the fact that TMEV is not neutralized by antibody and chronic infection is not aborted include the formation of complexes of infectious virus and antibody in the CNS and the production of antibodies with low affinity for TMEV.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 203636     DOI: 10.1093/infdis/137.2.145

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  30 in total

1.  Determinants of persistence and demyelination of the DA strain of Theiler's virus are found only in the VP1 gene.

Authors:  F Tangy; A McAllister; C Aubert; M Brahic
Journal:  J Virol       Date:  1991-03       Impact factor: 5.103

2.  Neutralizing monoclonal antibodies to Theiler's murine encephalomyelitis viruses.

Authors:  S Nitayaphan; M M Toth; R P Roos
Journal:  J Virol       Date:  1985-02       Impact factor: 5.103

3.  Treatment of Theiler's virus-induced demyelinating disease with teriflunomide.

Authors:  Francesca Gilli; Libin Li; Darlene B Royce; Krista D DiSano; Andrew R Pachner
Journal:  J Neurovirol       Date:  2017-09-14       Impact factor: 2.643

4.  Antigenic variants are not selected during persistent infection with Theiler's virus.

Authors:  J L Leibowitz; M Rodriguez
Journal:  Infect Immun       Date:  1983-07       Impact factor: 3.441

5.  Characterization of a cell culture persistently infected with the DA strain of Theiler's murine encephalomyelitis virus.

Authors:  R P Roos; O C Richards; J Green; E Ehrenfeld
Journal:  J Virol       Date:  1982-09       Impact factor: 5.103

6.  A neutralization-resistant Theiler's virus variant produces an altered disease pattern in the mouse central nervous system.

Authors:  A Zurbriggen; R S Fujinami
Journal:  J Virol       Date:  1989-04       Impact factor: 5.103

Review 7.  Theiler's virus infection: a model for multiple sclerosis.

Authors:  Emilia L Oleszak; J Robert Chang; Herman Friedman; Christos D Katsetos; Chris D Platsoucas
Journal:  Clin Microbiol Rev       Date:  2004-01       Impact factor: 26.132

8.  Theiler's virus persistence and demyelination in major histocompatibility complex class II-deficient mice.

Authors:  M K Njenga; K D Pavelko; J Baisch; X Lin; C David; J Leibowitz; M Rodriguez
Journal:  J Virol       Date:  1996-03       Impact factor: 5.103

9.  Localization of a neutralization site of Theiler's murine encephalomyelitis viruses.

Authors:  S Nitayaphan; M M Toth; R P Roos
Journal:  J Virol       Date:  1985-12       Impact factor: 5.103

10.  Restricted virus replication in the spinal cords of nude mice infected with a Theiler's virus variant.

Authors:  A Zurbriggen; M Yamada; C Thomas; R S Fujinami
Journal:  J Virol       Date:  1991-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.